Dublin, July 06, 2023 (GLOBE NEWSWIRE) -- The "RNA Analysis Market Size, Share & Trends Analysis Report By Product (Kits & Reagents, Services, Instruments), By Technology (qPCR, Microarray, Sequencing), By Application, By End-use And Segment Forecasts, 2023-2030" report has been added to ResearchAndMarkets.com's offering.
The global RNA analysis market size is expected to reach USD 20.21 billion by 2030, registering a CAGR of 10.86%
Transcriptomics is one of the most advanced fields in the post-genomic period. Technological advancements in this industry can be attributed to the increasing applications of transcriptome sequencing in life science for capturing polyadenylated RNA.
With the expansion of next-generation high-throughput sequencing technology, the analysis of transcriptomes has been gradually improving the understanding of the regulatory network of RNA-based genes. For instance, in July 2021, the Lithuanian team is developing a droplet-based technique for simultaneous mRNA and microRNA capture and sequencing in a single cell.
The research is backed by the European Union with a USD174,000 Horizon 2020 research grant. Moreover, in May 2022, CD Genomics launched the Digital RNA sequencing technology, which is an NGS-based method that excludes sequence-dependent PCR. Such initiatives are anticipated to accelerate market growth shortly.
Ribonucleic acid transcriptome analysis enables the researchers to analyze the position of genes as well as the functional patterns of a specific gene in an organism. The method assists in evaluating every transcript's changing behavior at the development stage and assesses all the elements of a transcript, including messenger ribonucleic acid, non-coding ribonucleic acid, and micro ribonucleic acid, for identifying the transcriptional structure of genes.
The growing need for analyzing a huge number of genes to understand the gene-to-drug interactions is anticipated to enhance the application of transcriptomics technologies in discovery applications and drug development. For instance, transcriptome profiles of COVID-19 patients have been analyzed to examine the disease prognosis and management.
Furthermore, increasing demand for personalized medicines is anticipated to fuel the industry growth during the forecast period. In April 2020, Caris Life Sciences announced the submission of Pre-Market Approval applications for MI Transcriptome CDx to the USFDA. It is a powerful precision medicine assay, which contains significant companion diagnostic biomarkers. On the other hand, data management in transcriptomic research and the lack of effective bioinformatics tools are some of the major challenges in the industry.
The evolution of high-throughput technologies has provided invaluable opportunities for generating holistic views of complex biological processes. Despite the considerable availability of omics data, the conversation of biological data into clinically valuable knowledge remains one of the major challenges.
It is not only because of insufficient current data processing or integration methods but also for inappropriate application of existing analysis approaches. North America has been reported as the highest revenue-generating region in 2021 owing to increasing investments in pharmaceutical and biotechnology research by corporations. Asia Pacific is projected to register the fastest CAGR from 2022 to 2030 owing to the low-cost manufacturing services.
RNA Analysis Market Report Highlights
- Real-Time- PCR (qPCR) accounted for the major market share in the technology segment in 2022 and is said to continue the trend during the forecast period owing to the increasing use of PCR for COVID-19 diagnostic across the globe
- The transcriptome sequencing technology is estimated to register a significant CAGR during the forecast period owing to factors, such as advancements in sequencing technology and growing acceptance of NGS technology
- The kits and reagents segment accounted for the highest revenue share in 2022 owing to a high utilization rate of consumables during transcriptomic studies
- The infectious diseases and pathogenesis segment accounted for the largest share in 2022 and is anticipated to have a similar trend during the forecasted period
- The increasing prevalence of the infectious disease is the major factor driving the segment growth
- Government institutes & academic centers dominated the end-user segment as the increasing number of institutes and centers leveraged high throughput technologies for the effective and efficient process of ribonucleic acid analysis
Market Dynamics
Market Driver Analysis
- Increasing Demand for Transcriptomics in Cancer Personalized/Precision Medicine
- Rising Diagnostic Utility Of Transcriptomics Technologies
- Advent of Novel Approaches for Understanding Gene Expression at RNA Level
Market Restraint Analysis
- Higher Cost of Research & Developments
- High Costs Associated With Analysis Platforms
Industry Analysis Tools
- Porter's Five Forces Analysis
- PESTEL Analysis
- COVID-19 Impact Analysis
Companies Mentioned
- Agilent Technologies, Inc
- F. Hoffmann-La Roche AG
- Illumina, Inc.
- QIAGEN
- Thermo Fisher Scientific, Inc.
- Eurofins Scientific
- Merck KGaA
- Bio-Rad Laboratories, Inc.
- Pacific Bioscience of California, Inc.;
- Affymetrix, Inc.
- Danaher
- Promeg
For more information about this report visit https://www.researchandmarkets.com/r/wjk58j
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
